{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-098229","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2022-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.214589+00:00","generated_at":"2026-06-26T08:47:39.804636+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Trevi Therapeutics raises ~$55M in private placement; amends SVB loan facility","bullets":["Gross proceeds ~$55M from sale of 4.58M shares at $1.90/share and pre-funded warrants for 24.38M shares at $1.899.","Co-lead investors: Frazier Life Sciences and Venrock; also Fairmount and New Enterprise Associates participating.","Proceeds to fund clinical development of Haduvio for chronic cough in IPF patients and for working capital.","Loan amendment with SVB: upon raising $45M net equity, milestones terminate; interest rate becomes prime+3% (floor 6.25%)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-098229","json":"https://secwatch.observer/filing/0001193125-22-098229.json","markdown":"https://secwatch.observer/filing/0001193125-22-098229.md","text":"https://secwatch.observer/filing/0001193125-22-098229.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000119312522098229/0001193125-22-098229-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000119312522098229/d324144d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T08:47:39.804636+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}